Menu
Search
|

Menu

Close
X

Neurotrope Inc NTRP.OQ (NASDAQ Stock Exchange Capital Market)

9.99 USD
-0.27 (-2.63%)
As of Jul 20
chart
Previous Close 10.26
Open 10.20
Volume 2,723
3m Avg Volume 5,836
Today’s High 10.34
Today’s Low 9.90
52 Week High 11.90
52 Week Low 3.41
Shares Outstanding (mil) 7.90
Market Capitalization (mil) 40.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.252
FY17
-1.649
FY16
-7.644
FY15
-11.413
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
1,251.45
Price to Sales (TTM)
vs sector
--
2.87
Price to Book (MRQ)
vs sector
2.06
2.28
Price to Cash Flow (TTM)
vs sector
--
15.64
Total Debt to Equity (MRQ)
vs sector
0.00
16.66
LT Debt to Equity (MRQ)
vs sector
0.00
8.90
Return on Investment (TTM)
vs sector
-106.77
13.72
Return on Equity (TTM)
vs sector
-172.55
13.63

EXECUTIVE LEADERSHIP

Joshua Silverman
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Daniel Alkon
President, Chief Scientific Officer, Since 2016
Salary: --
Bonus: --
Charles Ryan
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
William Singer
Vice Chairman of the Board, Since 2013
Salary: --
Bonus: --
Robert Weinstein
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $240,000.00
Bonus: $50,000.00

COMPANY PROFILE

Sector: Technology
Industry: Software
Address:

205 E 42nd St Fl 17
NEW YORK   NY   10017-5751

Phone: +1973.2420005
Site:

Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD.

SPONSORED STORIES